Estee Lauder Gains, Imax Jumps, Denali Therapeutics Slides After Parkinson’s Drug Trial Failure

On this episode of Stock Movers:
- Estee Lauder (EL) shares gain. The US beauty company and Spanish firm Puig confirmed talks about a potential business combination have ended. Analysts cite several reasons for the positive reaction to the termination of talks, including “aversion to large deals,” integration risk/potential dilution to shareholders, as well as distraction to core business and its Beauty Reimagined strategic plan. Some analysts see better M&A opportunities in fragrance, or in masstige/mass segments.
- Imax (IMAX) shares jump. The Wall Street Journal reported the large-screen theater company is exploring a sale and has approached entertainment companies as potential buyers. The sale process is in early stages and may not result in a deal, the report states, citing people familiar with the situation
- Denali Therapeutics (DNLI) shares slide. The drug developer said a mid-stage study of an experimental therapy for Parkinson’s disease, with partner Biogen, did not meet its primary or secondary endpoints.

See omnystudio.com/listener for privacy information.